However, the decision of who will make the HPV vaccines will depend on the outcome of a 2012 Supreme Court case. As on today, two HPV vaccines are available in India, developed by Merck Sharp & Dohme (MSD) and GlaxoSmithkline (GSK), while one vaccine developed by an Indian firm is in clinical trials. Around 24,000 pre-adolescent girls were given MSD and GSK vaccines in the trial, overseen by the Indian Council of Medical Research (ICMR) and DCGI. But opponents of the HPV vaccine say it is unnecessary, because screening for cervical cancer alone can prevent many deaths. Since the introduction of HPV vaccines worldwide, Japan and Denmark have reported some cases of autoimmune illnesses in vaccine recipients.

Source: The Hindu January 24, 2018 16:39 UTC